All posts by student

FDA approval for 23andMe’s direct-to-consumer genetics test – pharmaphorum

In a landmark decision from the FDA, genomics firm 23andMes direct-to-consumer genetics test has been approved in 10 conditions.

Originally given FDA marketing authorisation in February 2015 as a personal genetics test for Bloom syndrome, US patients can now bypass their doctors and perform at-home genetic tests using 23andMes Personal Genome Service to determine their risk of developing specific diseases.

However the FDA has approved the tests as a guide to potential risks, and has said they should not be used as a diagnostic tool.

The 10 conditions the Personal Genome Service now has marketing approval in are:

Thetest itself involves analysing DNA taken from a saliva swab. The sample is sent via post to a 23andMe lab which returns results in around six weeks.

Similar tests are already available to patients but only through their doctors. The most notable example is Myriad Genetics myRisk a 28-gene panel for determining predisposition to a number of cancer types. The test raked in $632 million in sales last year for the company.

This is an important moment for people who want to know their genetic health risks and be more proactive about their health, said Anne Wojcicki, 23andMe CEO and co-founder. The FDA has embraced innovation and has empowered individuals by authorising direct access to this information. It is a significant step forward for 23andMe and for the adoption of personal genetics.

The approval contrasts with the FDAs 2013 decision to prevent 23andMe from selling its genetic tests on the basis that inaccurate results could misinform patients.

As a work-around, 23andMe marketed its test as an ancestry kit to determine whether patients were carriers of genetic mutations associated with particular diseases. It did not however offer genetic health reports.

Regardless of its high-profile backing from entitieslike Google Ventures, the jury is still out as to whether genetic tests will in fact be beneficial and not simply overload doctors with patients demanding specific therapies based on their genetic health reports.

Chief medical officer for England, Dame Sally Davies, remains on the fence about the products,as evidenced by her recent interview with the Financial Times:We are going to have to explain to the public that there are cowboys out there giving you data that they dont understand and we wont be able to explain, said Davies. I think theres an element of that with 23andMe, although they do report back quite effectively.

Read more:
FDA approval for 23andMe's direct-to-consumer genetics test - pharmaphorum

How octopuses, squid, and cuttlefish defy genetics’ ‘central dogma’ – Phys.Org

April 6, 2017 This visual abstract depcits the findings of Liscovitch-Brauer et al., who show behaviorally complex cephalopods use extensive RNA editing to diversify their neural proteome at the cost of limiting genomic sequence flexibility and evolution. Credit: Liscovitch-Brauer et al./Cell 2017

Octopuses, squid, and cuttlefish often do not follow the genetic instructions in their DNA to the letter. Instead, they use enzymes to pluck out specific adenosine RNA bases (some of As, out of the As, Ts, Gs, and Us of RNA) that codes for proteins and replace them with a different base, called Inosine. This processcalled "RNA editing"is rarely used to recode proteins in most animals, but octopuses and their kin edit RNA base pairs in over half of their transcribed genes. When researchers did experiments to quantify and characterize the extent of this RNA editing across cephalopod species, they found evidence that this genetic strategy has profoundly constrained evolution of the cephalopod genome. The study appears in Cell on April 6.

Researchers have found that octopuses use RNA editing to rapidly adapt to temperature changes (DOI: 10.1126/science.1212795) and that the majority of RNA transcripts in squid neurons contain these edits (DOI: 10.7554/eLife.05198). In the new study, researchers hoped to find out how commonplace these edits are, how they evolved along the cephalopod lineage, and how such extraordinary editing capabilities affect the evolution of the cephalopod genome.

Vertebrate cells are capable of RNA editing, but we use it very rarely. Humans have 20,000 genes but only a few dozen conserved RNA editing sites that are likely encoding functional proteins. Squids also have about 20,000 genes but have at least 11,000 active RNA editing sites affecting the proteome, many of which are conserved, according to this study's estimates. "Basically, this is a mechanism to make proteins that are not encoded in the DNA. They are not present in the genomic sequence," says study co-author Eli Eisenberg, a biophysicist at Tel Aviv University in Israel. "With these cephalopods, this is not the exception. This is the rule. The rule is that most of the proteins are being edited."

In fact, RNA editing is so rare that it's not considered part of genetics' "Central Dogma." "Ever since Watson and Crick figured out that genetic information is stored in DNA, we've had this view that all the information is stored in DNA, and it's faithfully copied to another molecule when it's usedthat's RNA, and from there, it's translated into the proteins that do all the work. "And it's generally assumed that that's a pretty faithful process," explains study co-author Joshua Rosenthal, a cephalopod neurobiologist at the Marine Biological Laboratory in Woods Hole, MA. "What the squid RNA is showing is that that's not always the casethat, in fact, organisms have developed a potent means to manipulate information in RNA."

Analysis across different cephalopod species revealed that this pattern held true in two species of octopus, the common cuttlefish, and one species of squid, all of which belong to the "coleoid" subclass within cephalopods, which are-known for their complex hunting and social behaviors. However, when the researchers checked for signs of RNA editing in one of the octopus's more distant relatives, the chambered nautilus, they found much lower levels of RNA editing. RNA-editing levels were also low in the California Sea Hare, a non-cephalopod mollusk that the researchers used for comparison.

Extensive RNA editing turned out to have robust evolutionary consequences. RNA editing enzymes can only happen to base pairs that are surrounded by a large RNA superstructure. If the bases on either side of the editing target mutate, then the organism may lose the ability to edit that target. Avid RNA recoders, like octopuses and squid, cannot afford DNA mutations in their RNA-editable genes, so they've surrendered the benefits of a frequently mutating DNA genome in favor of RNA editing, the researchers found.

Most organisms extensively use splicing, the process of cutting or adding whole sections of RNA transcripts before they leave the nucleus, to diversify their proteomes, but prioritize DNA flexibility over RNA editing. "We usually think of evolution using whatever it can to answer some challengesso why was RNA recoding not used?" says Eisenberg. "Now, we have an example of what happens when we do use RNA editing abundantly. We know there's a price. The price is slowing down genome evolution...Cephalopods probably chose to take this RNA bargain over genome evolution, and maybe vertebrates made the other choicethey preferred genome evolution over editing."

Since many of the most heavily edited RNAs coded for key neural proteins, the researchers wonder whether RNA editing might contribute to the remarkable intelligence of octopuses and their kin. Not only are they smart enough to hunt, octopuses are clever enough to escape from jars, use coconut husks to hide themselves, signal to others by changing their skin color, and learn through observation.

"They're the only taxon out there that approaches vertebrates in terms of behavioral complexity," says Rosenthal. "These behaviorally complex coeloids all have this tremendous RNA editing, particularly in their nervous system, where they're recoding the messenger RNAs that encode for the very things that are important for electrical excitability."

Researchers are working on an octopus animal model to find out whether RNA editing plays a pivotal role in cephalopod behavior. Experiments that deal with the role of RNA editing in behavior will require an octopus that grows well in laboratories and can be genetically manipulated.

"RNA editing is an elegant system to add flexibility to your genetic information," says Rosenthal, "but it's a real challenge to figure out when it's being used and how it's being used."

Explore further: Squid enrich their DNA 'blueprint' through prolific RNA editing

More information: Cell, Liscovitch-Brauer et al.: "Trade-off between Transcriptome Plasticity and Genome Evolution in Cephalopods" http://www.cell.com/cell/fulltext/S0092-8674(17)30344-6 , DOI: 10.1016/j.cell.2017.03.025

Journal reference: Cell

Provided by: Cell Press

One of the surprising discoveries to emerge from the young field of comparative genomics is that drastically different organismshumans, sea urchins, worms, flies are endowed with a more or less common set of genes. ...

The principle of adaptationthe gradual modification of a species' structures and featuresis one of the pillars of evolution. While there exists ample evidence to support the slow, ongoing process that alters the genetic ...

New techniques in molecular biology that enable targeted interventions in the genome are opening up promising new possibilities for research and application. The ethical and legal ramifications of these methods, known as ...

A new study provides insight on the potential role played by RNA (ribonucleic acid) editing in cancer.

Gene editingone of the newest and most promising tools of biotechnologyenables animal breeders to make beneficial genetic changes, without bringing along unwanted genetic changes.

(PhysOrg.com) -- Researchers have discovered that when it comes to the survival of an octopus living in frigid waters, the reasoning is not a difference in the gene DNA but rather a difference in the RNA editing.

Researchers from the CNRS have discovered that mandrills use their sense of smell to avoid contamination by intestinal protozoans through contact with infected members of their group. Their work, published in Science Advances, ...

Birds show an amazing diversity in plumage colour and patterning. But what are the genetic mechanisms creating such patterns? In a new study published today in PLOS Genetics, Swedish and French researchers report that two ...

Walking through a grassy field or forest take a moment to consider what lies beneath the surface. A web of plant roots interacts symbiotically with arbuscular mycorrhizal (AM) fungi that extend their hyphae from the root ...

A new study of Peruvian frogs living at a wide variety of elevationsfrom the Amazon floodplain to high Andes peakslends support to the idea that lowland amphibians are at higher risk from future climate warming.

Humans are able to interpret the behaviour of others by attributing mental states to them (and to themselves). By adopting the perspectives of other persons, they can assume their emotions, needs and intentions and react ...

(Phys.org)A pair of biology professors, one with the University of Illinois, the other with Macquarie University in Australia has proposed in a Perspective piece in the journal Science that the traits we see as instinctual ...

Adjust slider to filter visible comments by rank

Display comments: newest first

Did Octopuses become "brains" in a hospitable environment which gave them more flexibility to form themselves whereas land creatures had to "build" complex systems to support their "brains" in a hostile environment ( air)?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Originally posted here:
How octopuses, squid, and cuttlefish defy genetics' 'central dogma' - Phys.Org

NewLink Genetics Unfairly Punished – Seeking Alpha – Seeking Alpha

The market punished NewLink Genetics (NASDAQ:NLNK) after presenting data on their indoleamine 2,3-dioxygenase (IDO) combination with Keytruda in advanced melanoma. The stock initially lost over 20% of its market value only to recover half of its losses and end the day down 10% after a number of analysts came to the company's defense. This article will explore whether the market overreacted to the data or if the data truly as bad as the market made it out to be.

IDO Inhibitor

IDO is a intracellular enzyme that regulates the immune response by degrading tryptophan to kynurenine. IDO pathway activity allows tumors to hijack the pathway to avoid the immune response.

The IDO pathway has gained a tremendous amount of hype in response to initial data released from Incyte (NASDAQ:INCY) at EMSO in 2016 as well as recently expanded trials in combination with PD-1 inhibitors with both Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) across a variety of tumor types. Immuno-oncology companies are looking to find the right combinations to provide synergistic benefits in areas where currently approved therapies are inadequate. While there is still limited available data, IDO inhibitors appear to be the front-runner to be one the first approved I-O combination with PD-1 across multiple tumor types.

NewLink Genetics

NewLink has wholly owned IDO inhibitor, Indoximod, as well as a partnered IDO inhibitor, GDC-0919, with Genentech/Roche. The company has two distinct strategies to target the IDO pathway. Indoximod acts directly on immune cells to reverse IDO pathway-mediated response. GDC-0919, like Incyte's epacadostat, is an enzymatic inhibitor, which blocks tryptophan metabolism.

NewLink's AACR presentation released data on Indoximod in combination with Keytruda to treat advanced melanoma. The interim data shows 60 patients treated, with 52 (87%) having stage IV melanoma. Importantly, NewLink included patients with difficult to treat Ocular Melanoma. In Merck's Keytruda phase 3 trial for melanoma, patients with ocular melanoma were excluded.

Source: AACR 2017

Across all 60 patients, there was a 52% objective response rate (12% complete response; 42% partial response), 22% stable disease, which resulted in a 73% disease control rate. Removing patients with ocular melanoma the ORR and DCR increase to 59% and 80%, respectively.

Source: AACR 2017

Source: AACR 2017

Good Results, Negative Reaction

Considering Keytruda's Phase 3 trial in advanced melanoma had a 33% ORR, it's clear adding an IDO inhibitor provides tremendous benefit. To understand why the market punished NewLink, we need to examine Incyte's IDO data with Keytruda in melanoma released at EMSO in 2016.

Source: EMSO 2016

Incyte presented a smaller data set comprising only 19 patients with advanced melanoma, none of which had ocular melanoma. Across all 19 patients, there was a 58% ORR (26% CR; 32% PR) and 74% DCR. Removing ocular melanoma patients from NewLink's data and you get strikingly similar data with one exception. Incyte's limited trial saw 26% of patients experience a complete response compared to just 12% in NewLink's trial.

Incyte's safety data presented at ESMO isn't apples to apples because the company included multiple tumor types, but Incyte's combination did include a higher number of grade 3/4 treatment related adverse events with 19% compared to NewLink's 6%. Importantly, no grade 4 or 5 events were reported in NewLink's data. This is an important distinction for the IDO combination, because the Opdivo/Yervoy combo saw a marked increase in adverse treatment related events. In Opdivo/Yervoy phase 3 trial in advanced melanoma the ORR was 59%, but grade 3/4 treatment related adverse events was 58%. This puts the IDO/PD-L1 at an advantage over Opdivo/Yervoy combo due to its comparably clean safety profile.

Balance Sheet

NewLink ended 2016 with $131.5 million in cash. The company expects a quarterly cash burn around $14 million, which would put the 2017 ending cash balance around $75 million. This excludes any possible milestone payments from Genentech, if they are able to advance their IDO partnership, GDC-0919, into Phase 2 during 2017. The bottom line remains NewLink has an acceptable cash balance to fund current studies well into 2018. Having said that, small cap biotechs are notorious for surprising investors by issuing new shares to raise capital. Investors should expect NewLink to raise funds sometime in the next 12-18 months.

Speculative Biotech Risks

As with all small cap biotech companies in the development stage, NewLink remains a high risk/high reward investment and should only be viewed as a speculative investment. While the company is targeting one of the hottest immuno-oncology pathways, there's no guarantee either of NewLink's IDO therapies will prove superior to Incyte's IDO program. A classic example of the risks in biotech is exemplified by NewLink's AACR presentation. The company reported encouraging data that was comparable to data released by Incyte, but the market did not give the company the benefit of the doubt and pushed shares down 20%. Investors who can't stomach volatility should probably look elsewhere.

Conclusion

IDO inhibitors are a huge step forward in combination with PD-L1 and paves the way for additional advancements in checkpoint inhibitors. It's too early to write off NewLink's proprietary IDO inhibitor, Indoximod. The data presented showed encouraging results in a broader patient population than has thus far been available. I believe the market has overreacted to what should be viewed as at the very least comparable data. Incyte may have shown a higher complete response rate, but in a far smaller data set. If it turns out Incyte's IDO enzymatic approach to block tryptophan metabolism is indeed superior to Indoximod mechanism of action, remember NewLink has a partnership with Genentech/Roche (OTCQX:RHHBY) utilizing the exact same approach. IDO inhibitors will remain a focal point for any company pursuing immuno-oncology and NewLink has distinguished itself as a major player with proven results in this area.

I'd recommend NewLink as a speculative buy on any continued weakness below $20/share. Data on IDO/PD-1 combinations should continue to be released throughout 2017 with ASCO in June as a likely event for Merck, Bristol-Myers or Roche to present data in areas outside of melanoma.

Disclosure: I am/we are long NLNK.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read the original here:
NewLink Genetics Unfairly Punished - Seeking Alpha - Seeking Alpha

New tool illuminates cell signaling pathways key to disease – Phys.org – Phys.Org

April 6, 2017

In a major advance for fundamental biological research, UC San Francisco scientists have developed a tool capable of illuminating previously inscrutable cellular signaling networks that play a wide variety of roles in human biology and disease. In particular, the technique opens up exciting new avenues for understanding and treating psychiatric disease, the researchers say.

The new technology, described in a paper published April 6, 2016 in Cell, makes it vastly easier for scientists to study the complex workings of a large family of sensor proteins called G-protein-coupled receptors (GPCRs), which sit in cell membranes and enable cells to respond to chemical signals from other parts of the body or the outside world. In a first proof-of-principle study, the UCSF team used their new approach to identify new biochemical players involved in the development of tolerance to opioid painkillerswhich target a particular type of GPCRfindings they anticipate will enable researchers to develop safer and more effective pain control.

"This technology will let us understand how these critical signaling molecules work in a way we've never been able to before," said Nevan Krogan, PhD, a professor of cellular and molecular pharmacology and director of the Quantitative Biosciences Institute (QBI) at UCSF and a senior investigator at the Gladstone Institutes, who was one of the new paper's senior authors.

Roughly 800 different types of GPCR play crucial roles throughout the body, including regulating heart rate, blood pressure and digestion; mediating the senses of sight, smell, and taste; and enabling many forms of chemical communication between cells in the brain. Approximately 40 percent of medicines target one type of GPCR or another, including schizophrenia drugs that target dopamine receptors, painkillers that target opioid receptors, and allergy and heartburn drugs that target different types of histamine receptors, just to name a few.

These many types of GPCR have one feature in common that makes them particularly difficult to study: when they are activated (whether by a beam of light or a blood-borne hormone), they set off a rapid cascade of biochemical reactions, in which the GPCRs themselves physically move from one location to another within the cell and trigger signals that are passed among dozens or hundreds of different protein messengers. Together, these changes end up altering a cell's behaviorfor example changing the excitability of neurons or reprogramming their genetic activity.

Technique Lets Scientist Sleuth Out Secretive Biochemical Networks

The last major breakthrough in understanding GPCR biology was the resolution of their chemical structure, research which garnered the 2012 Nobel Prize in Chemistry. But taking the next step towards understanding GPCR biology has been slow: without better tools for charting the chemical cascades triggered by GPCRs, it has been extremely challenging for researchers to get a clear picture of how these signals work, how they go awry in disease, or how to better control them with drugs. But Krogan and von Zastrow believe their new technique will change all that:

"The methodology that our collaborative team developed allows one to precisely define the local protein environment of receptors as they dynamically change partners and move within the cell," said Mark von Zastrow, MD, PhD, a professor of psychiatry and cellular and molecular pharmacology at UCSF and the paper's other senior author. "We ourselves were surprised by the high degree of spatial and temporal resolution that this methodology can achieve."

Postdoctoral researchers Braden T. Lobingier, PhD, and Ruth Httenhain, PhD, who were co-first authors on the new study, led the development of the new tool, which lets researchers study GPCR signaling cascades by operating like police detectives mapping the criminal network of a secretive crime boss: Starting with a list of proteins that are known collaborators of a particular GPCR, researchers trigger GPCR activity and use a biochemical tracking device to identify these proteins' associates in other parts of the cell.

To build this network of associates, the researchers turned their receptor of interest into an "informant" by outfitting it with a tracking device in the form of an enzyme called APEX, which can be triggered to spray any nearby proteins with a chemical tag. Researchers can then use this tag to track down and identify suspected participants in the GPCR cascade using a technique called mass spectrometry. By triggering APEX tagging at different times after activating the GPCR, the researchers were able to begin building a detailed and unbiased map of the protein network underlying a cell's response to activation of a particular GPCR.

Study Reveals Potential Mechanisms of Opioid Painkiller Tolerance

In a proof-of-principle experiment, Krogan and von Zastrow's team used their technique to answer a long-standing mystery about the biological mechanisms of opioid tolerancethe phenomenon by which, over time, patients tend to need higher and higher doses of opioid painkillers such as morphine to achieve the same level of pain management.

This is an important puzzle to solve, because increased opioid use in response to tolerance puts patients at risk of serious adverse side effects and also promotes addiction. Researchers know that tolerance occurs when cells respond to long-term opioid use by destroying or "down-regulating" the GPCR opioid receptors that these drugs target, but what triggers cells to do this is unknown.

Using their APEX-based tool, the UCSF researchers found that two cellular proteins not previously known to interact with opioid receptors in fact partner closely with delta-opioid receptors (a subtype of opioid receptor) at precisely the time and place at which the cell targets these receptors for destruction. They then confirmed, using genetic manipulations, that both proteins are essential for the down-regulation process.

Understanding the protein partners involved in opioid tolerance could enable researchers to develop improved pain control strategies, or adapt present strategies to be safer and more effective, the researchers say.

Krogan and von Zastrow emphasize that not all suspects revealed by their technique will prove to be important in a given GPCR cascade. But the ability to quickly and easily identify likely participants in a given cascade should dramatically quicken the pace toward understanding these complex signaling processes, and to develop more targeted treatments for diseases in which they go awry.

Researchers Set Their Sights on Common Mechanisms of Psychiatric Disease

Krogan and von Zastrow are particularly interested in the many classes of GPCR that mediate chemical signaling in the brain. The new approach is the centerpiece of a new large-scale collaborative project Krogan and colleagues are launching within QBI, called the Psychiatric Cell Mapping Initiative, the goal of which is to understand how abnormal biochemical network activity in different cell types in the brain might contribute to many different psychiatric disorders.

Most of the brain's chemical signals - neurotransmitters such as dopamine, serotonin, glutamate, and GABA - bind to their own class of GPCR to influence brain activity. These neurotransmitter receptors are deeply involved in many psychiatric diseases, including major depression, schizophrenia, and addiction, and are the targets of many psychiatric and psychoactive drugs.

"We still know so little about the biology of psychiatric disease, and even less about psychiatric drugs," Krogan said. "Our goal with this initiative is to use this and other new tools to gain a better understanding of the common cell biology behind major psychiatric diseases. This new tool will let us study how GPCRs work differently in psychiatric diseases, which could help us understand why these disorders arise, and will also let us test how psychiatric drugs actually alter the workings of their target cells in a way no one has ever been able to before."

Explore further: How proteins find one another

More information: Cell (2017). dx.doi.org/10.1016/j.cell.2017.03.022

Researchers from Charit Universittsmedizin Berlin have been studying two proteins that play a vital role in many bodily processes. The aim of the research was to establish how G-protein-coupled receptors (GPCRs) and ...

Cholesterol may act as a selective glue that binds proteins into paired structures that enable human cells to respond to outside signals, according to a new study in PLOS Computational Biology.

For the first time, scientists from the Florida campus of The Scripps Research Institute (TSRI) have created detailed "fingerprints" of a class of surface receptors that have proven highly useful for drug development.

Antipsychotic drugs, used in the treatment of psychotic disorders involving severe delusions and hallucinations, have been studied for more than 70 years. Currently available antipsychotic drugs, however, only alleviate certain ...

A study led by researchers at the Hospital del Mar Medical Research Institute (IMIM) and the Faculty of Medicine in Charit Hospital, Berlin demonstrates that the cholesterol present in cell membranes can interfere with ...

G protein-coupled receptors (GPCRs) are the largest class of cell surface receptors in our cells, involved in signal transmission across the cell membrane. One of the biggest questions is how a signal recognized at the extracellular ...

Researchers from the CNRS have discovered that mandrills use their sense of smell to avoid contamination by intestinal protozoans through contact with infected members of their group. Their work, published in Science Advances, ...

Birds show an amazing diversity in plumage colour and patterning. But what are the genetic mechanisms creating such patterns? In a new study published today in PLOS Genetics, Swedish and French researchers report that two ...

Walking through a grassy field or forest take a moment to consider what lies beneath the surface. A web of plant roots interacts symbiotically with arbuscular mycorrhizal (AM) fungi that extend their hyphae from the root ...

A new study of Peruvian frogs living at a wide variety of elevationsfrom the Amazon floodplain to high Andes peakslends support to the idea that lowland amphibians are at higher risk from future climate warming.

Humans are able to interpret the behaviour of others by attributing mental states to them (and to themselves). By adopting the perspectives of other persons, they can assume their emotions, needs and intentions and react ...

(Phys.org)A pair of biology professors, one with the University of Illinois, the other with Macquarie University in Australia has proposed in a Perspective piece in the journal Science that the traits we see as instinctual ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Original post:
New tool illuminates cell signaling pathways key to disease - Phys.org - Phys.Org

Anatomy Of A Masterpiece: The Making Of ‘Pet Sounds’ – MediaPost Communications

If the Beach Boys' "Pet Sounds" album was such a masterpiece, why did they end up being depicted on its cover cavorting with a bunch of goats?

Band member Al Jardine provides the answer in a documentary about the 1966 album that premieres on Showtime Friday night (April 7).

Basically, says Jardine, the suits at Capitol Records didnt understand the record because its sound and subject matter had veered so far away from the formula that had made the Beach Boys successful up to that time, which was surfing and hot-rod records.

They just didnt understand it ," Jardine says in the one-hour documentary, titled "The Beach Boys: Making Pet Sounds." "They didnt know what to do with it.

advertisement

advertisement

"Theyre a marketing firm, he said of Capitol. How do you market [the] Beach Boys with 'Pet Sounds'? Well, we'll send you down to the San Diego Zoo and well photograph you with a bunch of damn goats. I mean, whats that all about? That was the biggest miscarriage of justice of all," he says with a laugh.

Like so many other masterpieces throughout the histories of various arts, "Pet Sounds" did not sell well at the outset, nor was it critically acclaimed.

"It took 20 years for it to go platinum, which was ridiculous," says Beach Boy Mike Love in the documentary, although the doc implies that even Love wasnt entirely on board with this new direction in the Beach Boys music.

As the documentary makes clear, "Pet Sounds" was a pet project of Brian Wilson (seen in the above photo, left, producing the album). No one argues that Wilson had been the genius behind the Beach Boys sound from the very beginning.

Wilson was interviewed at length for this documentary, and he appears frequently in it. In pushing the record company and his bandmates to participate in the production of "Pet Sounds," Wilsons goal was largely a creative one: He wanted to "write something better than surf songs and car songs," he explains.

The result was an album whose best-known songs are the singles "Wouldnt It Be Nice" and "God Only Knows." True fans of the album know the rest of the songs just as well, including "Thats Not Me," "Dont Talk (Put Your Head On My Shoulder)," "I Know Theres an Answer," "I Just Wasnt Made for These Times" and the instrumental "Pet Sounds."

This fascinating documentary makes a strong case for the albums status as a masterpiece of the recording arts. The film delves deeply into how the sounds on "Pet Sounds" were produced. Testimony is given by many who were there, including members of the group of L.A. recording session players known as The Wrecking Crew.

Among those interviewed is Tony Asher, co-writer on eight of the songs on "Pet Sounds." Asher, who had been a composer of commercial jingles before "Pet Sounds, tells a great story about meeting Brian Wilson by happenstance in a hallway at a recording studio where they were both working. From that meeting, they forged an unlikely songwriting partnership.

Among other things, various witnesses note that Wilson was a fan of Phil Spectors "Wall of Sound" approach to making records, and under Wilsons direction, the "Pet Sounds" recording sessions featured an ever-growing body of musicians.

For example, there was not one piano, but usually three, remembers one interview subject.

For all the challenges and difficulties that went into making "Pet Sounds," the documentary gives the impression that the record company execs thought well enough of Wilson that they dont seem to have exerted any disruptive efforts to rein him in as the recording sessions dragged on and the studio became full of musicians who needed to be paid.

As for the goat photo on the album jacket, maybe no one ever explained to the Capitol execs what the title "Pet Sounds" was supposed to mean in the first place. Ironically, its not explained in the documentary either.

"The Beach Boys: Making Pet Sounds" premieres Friday night (April 7) at 8 Eastern on Showtime.

Read more:
Anatomy Of A Masterpiece: The Making Of 'Pet Sounds' - MediaPost Communications

Shonda Rhimes, creator of ‘Grey’s Anatomy’ and ‘Scandal’, joins Planned Parenthood board – Washington Post

Shonda Rhimes, one of Hollywoods most popular and powerful women, has joined the national board of Planned Parenthood.

Rhimes, creator and producer of prime-time television shows Greys Anatomy and Scandal, assumes a formal role in the organization at a time when antiabortion activists and some Republican lawmakers have set their sights on defunding Planned Parenthood.

The fact is that womens health is under fire right now, Rhimes said in an interview with Elle Magazine, which first reported the news. And so to me, it feels like its important to help fight back.

Rhimes has used her shows to present leading female characters who are celebrated for exercising their agency, and for exploring a range of social issues including abortion. Olivia Pope, the heroine of Scandal, had an abortion in a 2015 episode that also included a floor fight in Congress over defunding Planned Parenthood. In 2011, a female character in Greys Anatomy also had an abortion.

[Scandal stuns views with an abortion scene]

Cecile Richards, president of Planned Parenthood, told Elle that the organization would look to use Rhimess creative energy and storytelling ability to educate the public about the organizations work.

And she couldnt be joining us at a better time, Richard said. When so much basic health care is under attack, as we saw just a few weeks ago as a room full of men negotiated away maternity benefits for women, its never been more important for peoples stories to be told.

She was referring to a much-criticized White House meeting in which President Trump and Vice President Pence met with members of the House Freedom Caucus to discuss a plan to repeal and replace the Affordable Care Act. Among the benefits under consideration for elimination was maternity care. The effort failed after factions within the GOP failed to agree on an overall plan. The Republican-led Congress also has been unable to come up with a measure to defund Planned Parenthood.

[Conservatives fall short of another goal: Defunding Planned Parenthood]

Anti-abortion groups and conservative lawmakers have for years sought to block the use of Medicaid funds to reimburse Planned Parenthood for services it provides to low-income patients. Federal law prohibits the use of Medicaid funds for abortions, except in the case of rape, incest or to the save the life of the mother.

Planned Parenthood has argued that the vast majority of its services involve providing basic gynecological health care, including Pap smears, offering low-cost contraceptives and providing referrals for other screenings, such as mammograms.

Rhimes, who has served on the Planned Parenthood Los Angeles board, told Elle that shes never used the organizations services but has friends who have.

The fact that Ive never had to use a Planned Parenthood, the fact that Ive never been in need of medical services I couldnt afford or didnt have access to, doesnt mean I shouldnt be concerned about the fact that other women dont have that access, she said.

Fans of Shonda Rhimes's shows already know Meredith Grey, Olivia Pope and Annalise Keating, and they're about to get acquainted with Alice Vaughan on "The Catch." Here's how Rhimes's newest TV drama uses some signature traits of a Shondaland show. (Nicki DeMarco/The Washington Post)

Read more here:
Shonda Rhimes, creator of 'Grey's Anatomy' and 'Scandal', joins Planned Parenthood board - Washington Post

New ‘Grey’s Anatomy’ Promo Traumatizes Fans With Plane Crash Flashbacks – Moviefone

Not again, Shonda! That's what we thought when we first heard that "Grey's Anatomy" Season 13 was setting an entire episode on a plane, with a crisis unfolding mid-flight, and that's what more fans are saying now that ABC has shared a promo for the hour.

We initially hoped the crisis would just be medical, and not a problem with the flight itself, but not only does there seem to be more than bad turbulence on the April 13 flight, "In the Air Tonight," the seriously bad flight is suffered, once again, by Meredith Grey (Ellen Pompeo).

Mer is probably still feeling traumatized by the loss of Lexie Grey (Chyler Leigh) in the Season 8 finale. If fans are still mourning Little Grey, she must be, too. The episode looks like it might be a bonding hour for Mer and Nathan Riggs (Martin Henderson) -- and they may join the Mile High Club while mid-air -- but still. The torture of Meredith Grey, and "Grey's fans, has not gone unnoticed.

"Grey's" fans reacted to the promo exactly as you might expect:

There are so many more tweets just like that. This plane *probably* won't crash, but it looks like everything else goes wrong, including some kind of medical issue. Mer just can't catch a break.

"Grey's Anatomy" Season 13 airs Thursdays at 8 p.m. on ABC.

Want more stuff like this? Like us on Facebook.

Link:
New 'Grey's Anatomy' Promo Traumatizes Fans With Plane Crash Flashbacks - Moviefone

Research Assistant (Physiology) – The Conversation Job Board – The Conversation AU

at Monash University

Job No. 561096 Faculty / Portfolio: Faculty of Medicine, Nursing and Health Sciences School of Biomedical Sciences Department of Physiology Location: Clayton campus Employment Type: Full-time Duration:12 month fixed-term appointment Remuneration: $64,563 - $74,160 pa HEW Level 05 (plus 9.5% employer superannuation)

Achieve at a world top 100 university

Clayton campus

If you're after a rewarding career, Monash University can help make it happen. With leading academics and world-class resources, combined with a ranking in the top 100 universities worldwide, we offer all you need to build a brighter future.

The Opportunity The Department of Physiology is seeking a highly motivated individual to join the research groups of two successful laboratories within the department. The selected candidate will assist with a variety of projects investigating the role of previously unlinked compounds on the metabolic status of mice.

You will be responsible for performing a range of researchrelated activities (including laboratory preparation, and operational and administrative duties) to support the delivery of in vivo physiology studies.

The role involves animal handling, monitoring and colony management; performing glucose tolerance tests, intraperitoneal / subcutaneous / intracerebroventricular injections, blood collection and sample processing; anaesthesia and implantation surgeries; and euthanasia and tissue harvest.

Ideally we are seeking a candidate who has completed a Bachelor of Science, Bachelor of Biomedical Science or equivalent degree, or someone who has substantial relevant skills and work experience leading to the development of practical expertise in metabolic research.

Enquiries Ms Lauren Kelly, Senior Project Manager, 03 9905 2377

Apply for this role.

If you apply for this position please say you saw it on The Conversation.

Monash University was established in 1958 and welcomed its first intake of students in 1961. In its fifty year history, the university has established itself as one of Australias finest tertiary institutions, building an enviable reputation for both its outstanding teaching and its transformative research. Today, Monash is Australias largest university, boasting a global network of more than 250,000 alumni.

More here:
Research Assistant (Physiology) - The Conversation Job Board - The Conversation AU

Episode 17: State of the Art – Coronary Physiology – TCTMD

State

Zip

Country Select a Country United States United Kingdom Australia Canada France New Zealand India Brazil Afghanistan land Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Cape Verde Cayman Islands Central African Republic Chad Chile China Colombia Comoros Democratic Republic of the Congo Republic of the Congo Cook Islands Costa Rica Cte d'Ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Faroe Islands Fiji Finland Gabon Gambia Georgia Germany Ghana Gibraltar Greece Grenada Guatemala Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Micronesia Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Curacao Nicaragua Niger Nigeria Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Romania Russia Rwanda Saint Kitts and Nevis Saint Lucia Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon Islands Somalia South Africa Spain Sri Lanka Sudan Suriname Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Tuvalu Uganda Ukraine United Arab Emirates United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands, British Virgin Islands, U.S. Yemen Zambia Zimbabwe

Read the original:
Episode 17: State of the Art - Coronary Physiology - TCTMD

Adoption Of Bow Use In Ancient Hunting May Have Set Off Societal Changes – New Hampshire Public Radio

At a point during human prehistory, hunters' reliance on the spear-thrower, or atlatl, shifted to another kind of weapon the self-bow.

This change happened on multiple continents (though bows never really caught on in Australia, where atlatls tended to yield only later, to firearms).

The first bows we know of conclusively, from archaeology, come from pine arrow shafts found at a bog site in Germany called Stellmoor, dating to around 11,000 years ago. Though, it's possible bows were in use much earlier in Africa.

Why did the bow replace the atlatl, and what social consequences may have followed from that shift? These are questions being asked by University of Wyoming PhD candidate in anthropology Brigid Sky Grund in a new paper in American Anthropologist, from which I took the above information.

As Grund notes in the article, most theories about this shift have pointed to the bow's greater accuracy and faster reload rate in hunting smaller fauna or in warfare. But Grund herself is looking instead at a different factor: the comparative learnability of each weapon. She writes:

"Most studies of bow and atlatl performance characteristics focus on the inherent qualities of the weapons themselves, neglecting to consider that functional weapons are wielded by capable individuals of various ages, sexes, strengths, dexterities, and skill levels."

I like this insight, because it puts people, in all our formidable variation, back into the equation, front and center. It's a dynamic-systems analysis if you will, in which a weapon and its user are inseparable.

In her analysis of learnability, Grund uses modern-day, long-term data sets up to eight years' worth from competitors participating in the World Atlatl Association International Standard Accuracy Contest (ISAC) and the Society for Creative Anachronism Inter-Kingdom Archery Competition (IAC).

Because she was able to track individual competitors' scores over time, she could see something about the rapidity of the learning curve for each weapon. As it turned out, individuals' atlatl scores increase rapidly right from the start, whereas people's bow scores don't in fact only in the fourth year of competition do bow users begin to approach maximum skill level.

In addition, youth scores from the two competitions, taken together with anthropological data on real-world hunting-weapon use, show that "biological constraints may preclude juveniles from wielding bows until later ages than atlatls."

Grund thinks, then, that less strong weapon users in the past based on contemporary differences in strength and dexterity in men and women, this group was likely to have included some women as well as juveniles may have been more likely to learn how to use an atlatl effectively. The stronger, skilled members of a population would, then, be the ones more likely to readily learn how to use a bow successfully.

In an email message last week, Grund elaborated on this point:

"If entire family groups comprised of people of varying ages, sexes, and strengths wield projectile technologies as part of hunting parties, atlatls may be favored over bows because they are accessible to wider segments of human populations.

On the other hand, if only a few individuals from a family or cultural group are required to participate in hunting behavior, then the exclusivity of bow technology might not matter, since projectiles would only be wielded by a few hunting specialists within that group."

It's that line of reasoning that leads Grund straight into the realm of prehistoric social behavior. In her paper, she concludes that the bow's favoring of highly skilled weapon users probably "exacerbated prehistoric social disparities and likely catalyzed emergent age- and-sex-based social divisions in prehistory."

If she's right, that's a broadly important finding in anthropology, because it clues us in to a cascade of major social changes in human groups over time.

But what about our why question: Why the shift from an easier-to-use to a harder-to-use hunting weapon?

Echoing the behavioral-ecology perspective in her paper, Grund said (excerpted from a lengthier answer):

"Chronologically, in many regions of the world, the adoption of bow technology seems to be coarsely correlated with a broadening of diet breadth and an increased preponderance of small game hunting.

Many human behavioral ecology studies of modern foragers have shown that under broad diet breadth and/or high resource stress conditions, the sexual division of labor increases. Therefore, a shift towards hunting smaller game under many prehistoric scenarios was likely associated with an increase in the division of labor, simply as a product of fluctuating resource exploitation strategies and dietary needs."

As she continues, Grund explains more precisely where the atlatl-to-bow shift comes in:

"Increased divisions of labor associated with broadened diet breadth and the appearance of hunting 'specialists' might cause a shift from atlatl to bow technology, and, reciprocally, the adoption of bow technology might inherently intensify emergent divisions of labor since it is less accessible to people of varying ages, sexes, strengths, and/or dexterities.

Though I haven't disentangled cause and effect yet, it seems that both the shift from atlatl to bow and chronologically associated fluctuations in resource exploitation strategies likely worked together to increase divisions of labor in prehistoric societies."

An acknowledgment that cause and effect can't easily be distinguished in this case is welcome. Still, I think Grund is on to something by thinking broadly about generalists versus specialists in weapon use.

In our prehistory, at certain times and places, individuals became more specialized for certain tasks that others in the group couldn't, or didn't, carry out and this in turn set social changes into effect. Precisely how human groups might be affected by the exclusion of certain group members from effective use of hunting technology such as bows may vary by region and will require new hypotheses and further work.

While discussing all this, I learned that for Grund, atlatls aren't merely academic. She threw her first atlatl dart back in high school, continued to experiment with atlatls during archaeology fieldwork, and in 2011 took first place in the novice/"non-regular competitor" women's division of an informal atlatl competition organized by the World Atlatl Association and the Wyoming Archaeological Society.

"We shot at homemade Pleistocene animal targets, including a paper mch mammoth," Grund explained.

That paper mch mammoth isn't credited in Grund's American Anthropologist paper. But who knows? Grund's hands-on experience may have played a role in her coming up with an innovative hypothesis about hunting patterns in our past.

Barbara J. King is an anthropology professor emerita at the College of William and Mary. She often writes about the cognition, emotion and welfare of animals, and about biological anthropology, human evolution and gender issues. Barbara's new book is Personalities on the Plate: The Lives and Minds of Animals We Eat. You can keep up with what she is thinking on Twitter: @bjkingape

See the rest here:
Adoption Of Bow Use In Ancient Hunting May Have Set Off Societal Changes - New Hampshire Public Radio